文献速递白血病

CEBPA突变白血病对MLL1复合物的遗传和药理学靶向敏感

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
PubMed 文献 · Leukemia · 2019-01-24

约10-15%的急性髓系白血病(AML)患者携带CEBPA突变。本研究发现致癌性C/EBPα p30与MLL1复合物在染色质上共定位并存在物理互作,敲除MLL1或药物抑制MLL1复合物可抑制CEBPA突变AML细胞增殖并恢复髓系分化潜能,提示MLL1复合物是潜在治疗靶点。

要点

  • 致癌性C/EBPα p30与MLL1复合物在全基因组染色质上共定位并存在强物理相互作用。
  • CRISPR/Cas9介导的MLL1突变导致表达C/EBPα p30的细胞增殖停滞和髓系分化。
  • 药物靶向MLL1复合物可损害携带CEBPA突变的小鼠和人类AML细胞增殖并恢复髓系分化潜能。

核心结论

  • C/EBPα p30需要MLL1复合物来调控致癌基因表达,CEBPA突变AML对MLL1复合物的扰动高度敏感。
  • 这些发现确定MLL1复合物是携带CEBPA突变的AML的潜在治疗靶点。

研究设计与样本

  • 本研究为实验性研究,包括CRISPR/Cas9介导的MLL1基因突变、染色质共定位和物理相互作用分析、以及药理学抑制实验,使用表达C/EBPα p30的细胞、CEBPA突变的造血祖细胞以及携带CEBPA突变的小鼠和人类AML细胞。

主要发现

  • 致癌性C/EBPα p30与MLL1在染色质上显示全局共定位,p30与MLL1复合物存在强物理相互作用。
  • CRISPR/Cas9介导的MLL1突变导致表达C/EBPα p30的细胞增殖停滞和髓系分化。
  • CEBPA突变的造血祖细胞对MLL1复合物的药理学靶向高度敏感。
  • 抑制剂治疗损害携带CEBPA突变的小鼠和人类AML细胞的增殖并恢复髓系分化潜能。
  • 转录因子GATA2被确定为p30-MLL1相互作用的直接关键靶点。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The gene encoding the transcription factor C/EBPα is mutated in 10-15% of acute myeloid leukemia (AML) patients. N-terminal CEBPA mutations cause ablation of full-length C/EBPα without affecting the expression of a shorter oncogenic isoform, termed p30. The mechanistic basis of p30-induced leukemogenesis is incompletely understood. Here, we demonstrate that the MLL1 histone-methyltransferase complex represents a critical actionable vulnerability in CEBPA-mutated AML. Oncogenic C/EBPα p30 and MLL1 show global co-localization on chromatin and p30 exhibits robust physical interaction with the MLL1 complex. CRISPR/Cas9-mediated mutagenesis of MLL1 results in proliferation arrest and myeloid differentiation in C/EBPα p30-expressing cells. In line, CEBPA-mutated hematopoietic progenitor cells are hypersensitive to pharmacological targeting of the MLL1 complex. Inhibitor treatment impairs proliferation and restores myeloid differentiation potential in mouse and human AML cells with CEBPA mutations. Finally, we identify the transcription factor GATA2 as a direct critical target of the p30-MLL1 interaction. Altogether, we show that C/EBPα p30 requires the MLL1 complex to regulate oncogenic gene expression and that CEBPA-mutated AML is hypersensitive to perturbation of the MLL1 complex. These findings identify the MLL1 complex as a potential therapeutic target in AML with CEBPA mutations.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Schmidt L, Heyes E, Scheiblecker L, et al. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia. 2019. PMID: 30679799. doi:10.1038/s41375-019-0382-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。